Loss of Foxp3+ Regulatory T cell Function in Glioblastoma (P4.240)

daniel e lowther,amanda l hernandez,xiangguo duan,murat gunel,david a hafler

DOI: https://doi.org/10.1212/wnl.84.14_supplement.p4.240

IF: 9.9

2015-01-01

Neurology

Abstract:OBJECTIVE: To understand the mechanism used by glioblastomas to escape immune surveillance. BACKGROUND: The immune response in tumors is characterized by a functionally suppressed cellular infiltrate with enrichment of CD4+CD25+CD127-Foxp3+ regulatory T cells (Treg) in the tumor microenvironment. It has been thought that tumor derived Tregs possess increased regulatory function owing to the presence of the co-inhibitory receptor PD-1 on their cell surface. DESIGN/METHODS: We isolated viable infiltrating lymphocytes from freshly resected tumors with matched peripheral blood of patients with glioblastoma and determined the functional efficacy of these cell populations. RESULTS: We observed increased expression of co-inhibitory molecules PD-1 and Tim3 on the surface of both Tregs and CD4+ effector T cells infiltrating the tumor microenvironment. Tumor-derived effector cells displayed impaired proliferative responses to anti-CD3/CD28 stimulation while exhibiting robust cytokine responses. Though present in the tumor in increased numbers, tumor derived Tregs surprisingly exhibited less ex vivo suppressor function as compared to matched circulating Tregs. Investigation of PD-1+ Tregs from the circulation of healthy controls revealed a similar phenotype with loss of ex vivo suppressor function associated with IFNγ secretion. CONCLUSIONS: These data indicate that the PD-1+ infiltrating tumor derived Tregs are dysfunctional and the impaired immune response in patients with glioblastomas is related to poor T effector cell function that may be amenable to anti-PD-1 therapy. Disclosure: Dr. Lowther has received research support from Bristol-Myers Squibb. Dr. Hernandez has nothing to disclose. Dr. Duan has nothing to disclose. Dr. Gunel has nothing to disclose. Dr. Hafler has received personal compensation for activities with Genzyme, NKT Therapeutics, and Novartis as a consultant.